ArticlePharmaceutical research2026
Domain Knowledge Constrained Symbolic Regression for Optimising Dermal Drug Formulations.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeInterpretable dynamic models that remain physically admissible under extrapolation are essential for dermal formulation optimisation. Mechanistic models are often labour-intensive to derive, whereas unconstrained data-driven models may violate physical constraints and degrade beyond observed conditions.
methodsWe developed a domain knowledge constrained symbolic regression (DKC-SR) framework to discover compact, interpretable dynamic models for cumulative release directly from time-series experiments. Domain knowledge was embedded through a restricted operator set and feasibility constraints over the bounded optimisation domain. Candidate expressions were evaluated by numerically solving the dynamic differential equations and selected using an information-criterion trade-off across a level-wise set of complexity-controlled models. The final surrogate was coupled with the covariance matrix adaptation evolution strategy for formulation optimisation.
resultsIn an ibuprofen formulation case study, the selected model provided a formulation ranking that, combined with experimental validation, guided the optimiser to a narrow high-performing region; a representative optimum was experimentally confirmed to exceed the historical best. Although the surrogate was more reliable for ranking and optimisation guidance than for exact quantitative calibration, it remained physically admissible and numerically stable across the design space.
conclusionsDKC-SR provides a compact, interpretable, and optimisation-ready route to modelling dermal release under bounded design constraints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.